Edith A Perez1,2, Karla V Ballman3, Afshin Mashadi-Hossein4, Kathleen S Tenner3, Jennifer M Kachergus2, Nadine Norton2, Brian M Necela2, Jennifer M Carr2, Sean Ferree4, Charles M Perou5, Frederick Baehner6, Maggie Chon U Cheang5,7, E Aubrey Thompson2. 1. Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL, USA. 2. Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL, USA. 3. Division of Biostatistics and Bioinformatics, Department of Health Science Research, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA. 4. Nanostring, Inc., Seattle, WA , USA. 5. Departments of Genetics and Pathology & Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. 6. Genonic Health, Inc., Redwood, CA, USA. 7. Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
Abstract
Background: Genomic data from human epidermal growth factor receptor 2-positive (HER2+) tumors were analyzed to assess the association between intrinsic subtype and clinical outcome in a large, well-annotated patient cohort. Methods: Samples from the NCCTG (Alliance) N9831 trial were analyzed using the Prosigna algorithm on the NanoString platform to define intrinsic subtype, risk of recurrence scores, and risk categories for 1392 HER2+ tumors. Subtypes were evaluated for recurrence-free survival (RFS) using Kaplan-Meier and Cox model analysis following adjuvant chemotherapy (n = 484) or chemotherapy plus trastuzumab (n = 908). All statistical tests were two-sided. Results: Patients with HER2+ tumors from N9831 were primarily scored as HER2-enriched (72.1%). These individuals received statistically significant benefit from trastuzumab (hazard ratio [HR] = 0.68, 95% confidence interval [CI] = 0.52 to 0.89, P = .005), as did the patients (291 of 1392) with luminal-type tumors (HR = 0.52, 95% CI = 0.32 to 0.85, P = .01). Patients with basal-like tumors (97 of 1392) did not have statistically significantly better RFS when treated with trastuzumab and chemotherapy compared with chemotherapy alone (HR = 1.06, 95% CI = 0.53 to 2.13, P = .87). Conclusions: The majority of clinically defined HER2-positive tumors were classified as HER2-enriched or luminal using the Prosigna algorithm. Intrinsic subtype alone cannot replace conventional histopathological evaluation of HER2 status because many tumors that are classified as luminal A or luminal B will benefit from adjuvant trastuzumab if that subtype is accompanied by HER2 overexpression. However, among tumors that overexpress HER2, we speculate that assessment of intrinsic subtype may influence treatment, particularly with respect to evaluating alternative therapeutic approaches for that subset of HER2-positive tumors of the basal-like subtype.
RCT Entities:
Background: Genomic data from human epidermal growth factor receptor 2-positive (HER2+) tumors were analyzed to assess the association between intrinsic subtype and clinical outcome in a large, well-annotated patient cohort. Methods: Samples from the NCCTG (Alliance) N9831 trial were analyzed using the Prosigna algorithm on the NanoString platform to define intrinsic subtype, risk of recurrence scores, and risk categories for 1392 HER2+ tumors. Subtypes were evaluated for recurrence-free survival (RFS) using Kaplan-Meier and Cox model analysis following adjuvant chemotherapy (n = 484) or chemotherapy plus trastuzumab (n = 908). All statistical tests were two-sided. Results:Patients with HER2+ tumors from N9831 were primarily scored as HER2-enriched (72.1%). These individuals received statistically significant benefit from trastuzumab (hazard ratio [HR] = 0.68, 95% confidence interval [CI] = 0.52 to 0.89, P = .005), as did the patients (291 of 1392) with luminal-type tumors (HR = 0.52, 95% CI = 0.32 to 0.85, P = .01). Patients with basal-like tumors (97 of 1392) did not have statistically significantly better RFS when treated with trastuzumab and chemotherapy compared with chemotherapy alone (HR = 1.06, 95% CI = 0.53 to 2.13, P = .87). Conclusions: The majority of clinically defined HER2-positive tumors were classified as HER2-enriched or luminal using the Prosigna algorithm. Intrinsic subtype alone cannot replace conventional histopathological evaluation of HER2 status because many tumors that are classified as luminal A or luminal B will benefit from adjuvant trastuzumab if that subtype is accompanied by HER2 overexpression. However, among tumors that overexpress HER2, we speculate that assessment of intrinsic subtype may influence treatment, particularly with respect to evaluating alternative therapeutic approaches for that subset of HER2-positive tumors of the basal-like subtype.
Authors: Aleix Prat; Giampaolo Bianchini; Marlene Thomas; Anton Belousov; Maggie C U Cheang; Astrid Koehler; Patricia Gómez; Vladimir Semiglazov; Wolfgang Eiermann; Sergei Tjulandin; Mikhail Byakhow; Begoña Bermejo; Milvia Zambetti; Federico Vazquez; Luca Gianni; José Baselga Journal: Clin Cancer Res Date: 2014-01-15 Impact factor: 12.531
Authors: Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; Nancy E Davidson; Charles E Geyer; Silvana Martino; Eleftherios P Mamounas; Peter A Kaufman; Norman Wolmark Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544
Authors: Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; George Sledge; Charles E Geyer; Silvana Martino; Priya Rastogi; Julie Gralow; Sandra M Swain; Eric P Winer; Gerardo Colon-Otero; Nancy E Davidson; Eleftherios Mamounas; Jo Anne Zujewski; Norman Wolmark Journal: J Clin Oncol Date: 2014-10-20 Impact factor: 44.544
Authors: Katherine L Pogue-Geile; Nan Song; Jong-Hyeon Jeong; Patrick G Gavin; Seong-Rim Kim; Nicole L Blackmon; Melanie Finnigan; Priya Rastogi; Louis Fehrenbacher; Eleftherios P Mamounas; Sandra M Swain; D Lawrence Wickerham; Charles E Geyer; Joseph P Costantino; Norman Wolmark; Soonmyung Paik Journal: J Clin Oncol Date: 2015-01-05 Impact factor: 44.544
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: Laura J Esserman; Donald A Berry; Maggie C U Cheang; Christina Yau; Charles M Perou; Lisa Carey; Angela DeMichele; Joe W Gray; Kathleen Conway-Dorsey; Marc E Lenburg; Meredith B Buxton; Sarah E Davis; Laura J van't Veer; Clifford Hudis; Koei Chin; Denise Wolf; Helen Krontiras; Leslie Montgomery; Debu Tripathy; Constance Lehman; Minetta C Liu; Olufunmilayo I Olopade; Hope S Rugo; John T Carpenter; Chad Livasy; Lynn Dressler; David Chhieng; Baljit Singh; Carolyn Mies; Joseph Rabban; Yunni-Yi Chen; Dilip Giri; Alfred Au; Nola Hylton Journal: Breast Cancer Res Treat Date: 2011-12-25 Impact factor: 4.872
Authors: Aleix Prat; Lisa A Carey; Barbara Adamo; Maria Vidal; Josep Tabernero; Javier Cortés; Joel S Parker; Charles M Perou; José Baselga Journal: J Natl Cancer Inst Date: 2014-08-19 Impact factor: 13.506
Authors: Mitch Dowsett; Ivana Sestak; Elena Lopez-Knowles; Kalvinder Sidhu; Anita K Dunbier; J Wayne Cowens; Sean Ferree; James Storhoff; Carl Schaper; Jack Cuzick Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544
Authors: Caterina Marchiò; Patrizia Dell'Orto; Laura Annaratone; Felipe C Geyer; Tiziana Venesio; Enrico Berrino; Ludovica Verdun di Cantogno; Andrea Garofoli; Nelson Rangel; Laura Casorzo; Carmine dell'Aglio; Patrizia Gugliotta; Elena Trisolini; Alessandra Beano; Francesca Pietribiasi; Renzo Orlassino; Paola Cassoni; Achille Pich; Filippo Montemurro; Marcella Mottolese; Anne Vincent-Salomon; Frédérique Penault-Llorca; Enzo Medico; Charlotte K Y Ng; Giuseppe Viale; Anna Sapino Journal: Am J Surg Pathol Date: 2018-09 Impact factor: 6.394
Authors: Ana Godoy-Ortiz; Alfonso Sanchez-Muñoz; Maria Rosario Chica Parrado; Martina Álvarez; Nuria Ribelles; Antonio Rueda Dominguez; Emilio Alba Journal: Front Oncol Date: 2019-10-29 Impact factor: 6.244
Authors: Tamara Díaz-Redondo; Rocio Lavado-Valenzuela; Begoña Jimenez; Tomas Pascual; Fernando Gálvez; Alejandro Falcón; Maria Del Carmen Alamo; Cristina Morales; Marta Amerigo; Javier Pascual; Alfonso Sanchez-Muñoz; Macarena González-Guerrero; Luis Vicioso; Aurora Laborda; Maria Victoria Ortega; Lidia Perez; Aranzazu Fernandez-Martinez; Nuria Chic; Jose Manuel Jerez; Martina Alvarez; Aleix Prat; Nuria Ribelles; Emilio Alba Journal: Front Oncol Date: 2019-11-05 Impact factor: 6.244